TG Therapeutics (TGTX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
The meeting was formally called to order and directors, auditors, and legal counsel were introduced.
The agenda included voting on three items as described in the proxy statement.
Board and executive committee updates
Directors nominated for election included Laurence N. Charney, Yann Echelard, Kenneth Hoberman, Daniel Hume, Dr. Sagar Lonial, and Michael S. Weiss, to serve until the 2027 annual meeting or until successors are elected.
Shareholder proposals
Three items were presented for shareholder voting: election of directors, ratification of KPMG LLP as auditors for 2026, and an advisory vote on executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from TG Therapeutics
- IV therapy for relapsing MS targets $1B run rate, with new dosing and sub-Q data expected soon.TGTX
H.C. Wainwright 28th Annual Global Investment Conference - BRIUMVI approaches $1B sales with expanded marketing, pipeline growth, and strong IP protection.TGTX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 revenue surged 64% year-over-year, driving raised guidance and strong liquidity.TGTX
Q2 2026 - Sub-Q launch and label updates aim to drive growth, expand market, and enhance patient experience.TGTX
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - SUB-Q BRIUMVI data signals major market expansion and strong competitive positioning.TGTX
Jefferies Global Healthcare Conference 2026 - Q1 2026 revenue hit $205M, guidance raised, and liquidity boosted by a $750M loan.TGTX
Q1 2026 - Annual meeting to elect directors, ratify auditor, and approve pay, with strong governance focus.TGTX
Proxy filing - Briumvi sales soared 350%+ in Q2, prompting raised guidance and operational profitability.TGTX
Q2 2024 - BRIUMVI's Q1 U.S. sales jumped 137%, raising 2025 guidance and fueling global expansion.TGTX
Q1 2025